Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC in the Treatment of Myelodysplastic Syndrome (MDS)
NCT03184935Phase 2Suspended
- Sponsor
- Sclnow Biotechnology Co., Ltd.
- Start
- Dec 2026
- Primary completion
- Jun 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of human umbilical cord derived mesenchymal stem cells in myelodysplastic syndrome (MDS), sponsored by Sclnow Biotechnology Co., Ltd.. Planned start Dec 2026; status: suspended.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03184935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184935.